Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass

Annals of Thoracic Surgery

Volumn 68, Issue 3, 1999, Pages 940-945

  Ray, Michael J ^b   Brown, Kaye F ^b   Burrows, Colin A ^a   O'Brien, Mark F ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032722138     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(99)00682-7     Document Type: Conference Paper

References (17)

1. Lemmer J.H., Dilling E.W., Morton J.R., et al. Aprotinin for primary coronary artery bypass grafting a multicenter trial of three dose regimens . Ann Thorac Surg. 62:1996;1659-1668.
2. Ray M.J., Marsh N.A., Perrin E.J., Just S.J.E., O'Brien M.F., Hawson G.A.T. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ann Thorac Surg. 63:1997;57-63.
3. Ray M.J., Marsh N.A. Aprotinin reduces bleeding after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost. 78:1997;1021-1026.
4. Lemmer J.H. Jr, Stanford W., Bonney S.L., et al. Aprotinin for coronary bypass operations efficacy, safety and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study . J Thorac Cardiovasc Surg. 107:1994;543-551.
5. Harmon D.E. Cost/benefit analysis of pharmacological hemostasis. Ann Thorac Surg. 61:1996;S21-S25.
6. Van Norman G., Lu J., Spiess B., Soltow L., Gillies B. Aprotinin versus aminocaproic acid in moderate-to-high-risk cardiac surgery relative efficacy and costs . Anesth Analg. 80:1995;SCA19.
7. Schonberger J.P., Everts P.A., Ercan H., et al. Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood savings. Ann Thorac Surg. 54:1992;1172-1176.
8. Concha M., Munoz I. Experience with low-dose aprotinin. Pifarré R. Blood conservation with aprotinin. 1995;293-312 Hanley & Belfus, Philadelphia.
9. Lathi K.G., Hariawala M., Fotouhi F., Symes J.F. Economics of aprotinin in cardiac surgery. Anesth Analg. 80:1995;SCA119.
10. Guest J.F., Munro V., Cookson R.F. The annual cost of blood transfusions in the United Kingdom. Clin Lab Haem. 20:1998;111-118.
11. Lubarsky D., Hahn C., Bennet D., et al. The hospital cost (fiscal year 1991/1992) of a simple perioperative allogenic red blood cell transfusion during elective surgery at Duke University. Anesth Analg. 79:1994;629-637.
12. Diefenbach C., Abel M., Limpers B., et al. Fatal anaphylactic shock after aprotinin re-exposure in cardiac surgery. Anesth Analg. 80:1995;830-831.
13. Dietrich W., Barankay A., Hahnel C., Richter J. High dose aprotinin in cardiac surgery three years' experience in 1,784 patients . J Cardiothorac Vasc Anesth. 6:1992;324-327.
14. Bidstrup B., Harrison J., Royston D., Taylor K., Treasure T. Aprotinin therapy in cardiac operations a report on use in 41 cardiac centers in the United Kingdom . Ann Thorac Surg. 55:1993;971-976.
15. Goldstein D.J., Oz M.C., Smith C.R., et al. Safety of repeat aprotinin administration for LVAD recipients undergoing cardiac transplantation. Ann Thorac Surg. 61:1996;692-695.
16. D'Errico C.C., Shayevitz J.R., Martindale S., Mosca R.S., Bove E.L. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg. 83:1996;1193-1199.
17. Lazzara R.R., Kidwell F.E., Kraemer M.F., Wood J.A., Starr A. Reduction in costs, blood products, and operating time in patients undergoing open heart surgery. Arch Surg. 132:1997;858-860.